ml298 and Glioblastoma

ml298 has been researched along with Glioblastoma* in 1 studies

Other Studies

1 other study(ies) available for ml298 and Glioblastoma

Article	Year
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells. Journal of medicinal chemistry, 2013, Mar-28, Volume: 56, Issue:6 An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells. Topics: Benzamides; Cell Line, Tumor; Cell Movement; Drug Discovery; Enzyme Inhibitors; Glioblastoma; Humans; Neoplasm Invasiveness; Phospholipase D; Spiro Compounds	2013

Article

Year

Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.

Journal of medicinal chemistry, 2013, Mar-28, Volume: 56, Issue:6

An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.

Topics: Benzamides; Cell Line, Tumor; Cell Movement; Drug Discovery; Enzyme Inhibitors; Glioblastoma; Humans; Neoplasm Invasiveness; Phospholipase D; Spiro Compounds

2013